tweenvest

HJ Science Co., Ltd. (SEHK: 6132)

Health Care · Biotechnology · CN

HK$32.44

-2.99% today · -8.0% 1Y

Public summary
A free snapshot of HJ Science Co., Ltd., with figures as of Nov 15, 2026. The full analysis is in the app.Open in the app

HJ Science Co., Ltd. (SEHK: 6132) operates in the Biotechnology industry within the Health Care sector. The company is valued at $304.32M and employs 113 people.

Over the last twelve months the share price has lost 8.0%, trading between 25.88 and 82.00.

Tweenvest scores HJ Science Co., Ltd. across four factors: quality 53/100, value 67/100. Its strongest factor is value.

6132 price history

Jun 26, 2026 · 44.08Weekly closes 26.80 – 51.30Nov 13, 2026 · 32.44

Key figures

Market cap
$304.32M
Revenue (TTM)
$2.08M
P/E
-10.82
EPS
-2.54
Dividend yield
—
Beta (5Y)
—
52-week high
HK$82.00
52-week low
HK$25.88
Avg volume (3M)
—
Shares outstanding
73.60M
Employees
113
Next earnings
—

About HJ Science Co., Ltd.

HJ Science Co., Ltd. is a clinical stage biotech company, which engages in research and development of small molecule drugs for tumors, autoimmune & metabolic system diseases for clinical treatments. It provides drug design, in vivo and in vitro activity evaluation, drug metabolism, synthesis, quality research, formulation development, and scale-up. Its products include HJ787, HJ178 and HJ891. The company was founded by Ji Jianxin on February 20, 2017 and is headquartered in Chengdu, China.

ISIN
CNE100007PD2
Founded
2017
Listed since
Jun 23, 2026
Exchange
The Stock Exchange of Hong Kong Ltd.
Currency
HKD
CompanyMarket capPriceDay
Scribe Therapeutics Inc.NasdaqGM: SCTX$309.82M$16.36-3.71%
Galectin Therapeutics Inc.NasdaqCM: GALT$307.59M$3.05-2.87%
Vector Science and Therapeutics Corp.TSXV: PAIN$307.08MCA$2.80+16.67%
Jiangsu Recbio Technology Co., Ltd.SEHK: 2179$306.59MHK$3.900.00%
Kyverna Therapeutics, Inc.NasdaqGS: KYTX$300.94M$4.76-5.74%
Vicore Pharma Holding AB (publ)OM: VICO$299.86MSkr10.72-2.37%
Century Therapeutics, Inc.NasdaqCM: IPSC$299.64M$1.65+1.23%
Evommune, Inc.NYSE: EVMN$299.37M$7.24+5.23%

Browse every Biotechnology company →